97 related articles for article (PubMed ID: 576232)
1. Sleep-related growth hormone release following 2-bromo-alpha-ergocriptine treatment in acromegalic patients.
Chihara K; Kato Y; Abe H; Furumoto M; Maeda K
J Clin Endocrinol Metab; 1977 Jan; 44(1):78-84. PubMed ID: 576232
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutical effects of bromocriptine (CB 154) in 10 acromegalic subjects. Study of somatotrophic function and clinical survey (author's transl)].
Fossati P; Asfour M; Brion-Brevan B; Fourlinnie JC; Cappoen JP; Dalle-Furnari MA; Blacker C
Ann Endocrinol (Paris); 1977; 38(4):291-301. PubMed ID: 332054
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients.
Chiodini PG; Liuzzi A; Muller EE; Botalla L; Cremascoli G; Oppizzi G; Verde G; Silvestrini F
J Clin Endocrinol Metab; 1976 Aug; 43(2):356-63. PubMed ID: 950367
[TBL] [Abstract][Full Text] [Related]
4. Effect of bromoergocriptine on TRH-induced growth hormone and prolactin release in acromegalic patients.
Ishibashi M; Yamaji T; Kosaka K
J Clin Endocrinol Metab; 1977 Aug; 45(2):275-9. PubMed ID: 407240
[TBL] [Abstract][Full Text] [Related]
5. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
6. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans.
Liuzzi A; Chiodini PG; Oppizzi G; Botalla L; Verde G; De Stefano L; Colussi G; Gräf KJ; Horowski R
J Clin Endocrinol Metab; 1978 Feb; 46(2):196-202. PubMed ID: 108287
[TBL] [Abstract][Full Text] [Related]
7. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.
Gelato MC; Oldfield E; Loriaux DL; Merriam GR
J Clin Endocrinol Metab; 1990 Sep; 71(3):585-90. PubMed ID: 2118536
[TBL] [Abstract][Full Text] [Related]
8. [The effect of Ritalin, CB-154 and various drugs of serum GH in acromegalics (author's transl)].
Kanatsuka A; Makino H; Matsushima Y; Osegawa M; Yamamoto M; Kumagai A
Nihon Naibunpi Gakkai Zasshi; 1978 May; 54(5):636-47. PubMed ID: 99332
[TBL] [Abstract][Full Text] [Related]
9. Bromocriptine reduces growth hormone in acromegaly.
Bell PM; Atkinson AB; Hadden DR; Kennedy L; Leslie H; Merrett JD; Sheridan B
Arch Intern Med; 1986 Jun; 146(6):1145-9. PubMed ID: 3718102
[TBL] [Abstract][Full Text] [Related]
10. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly.
Chiba T; Chihara K; Minamitani N; Goto B; Kadowaki S; Taminato T; Matsukura S; Fujita T
Horm Metab Res; 1982 Feb; 14(2):57-61. PubMed ID: 7040191
[TBL] [Abstract][Full Text] [Related]
11. Experiences with bromocriptine treatment in acromegaly--a preliminary report.
Nilsson A
Acta Endocrinol Suppl (Copenh); 1978; 216():217-24. PubMed ID: 274038
[TBL] [Abstract][Full Text] [Related]
12. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
13. [Fall of the growth hormone levels in acromegalics after bromocryptin (author's transl)].
Dolecek R
Cas Lek Cesk; 1976 Aug; 115(33-34):1056-7. PubMed ID: 989744
[No Abstract] [Full Text] [Related]
14. [Therapy of acromegaly using bromocriptine].
Köbberling J; Schwinn G; Dirks H
Dtsch Med Wochenschr; 1975 Jul; 100(29):1540-2. PubMed ID: 1149634
[TBL] [Abstract][Full Text] [Related]
15. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients.
Fedele D; Molinari M; Meneghel A; Valerio A; Muggeo M; Tiengo A
J Endocrinol Invest; 1980; 3(2):149-53. PubMed ID: 6993548
[TBL] [Abstract][Full Text] [Related]
17. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
Dallabonzana D; Liuzzi A; Oppizzi G; Verde G; Chiodini PG; Dorow R; Horowski R
J Endocrinol Invest; 1985 Apr; 8(2):147-51. PubMed ID: 4031381
[TBL] [Abstract][Full Text] [Related]
18. Effect of different dopaminergic agents in the treatment of acromegaly.
Colao A; Ferone D; Marzullo P; Di Sarno A; Cerbone G; Sarnacchiaro F; Cirillo S; Merola B; Lombardi G
J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
[TBL] [Abstract][Full Text] [Related]
19. Induction of growth hormone and prolactin secretion by luteinizing hormone-releasing hormone and its blockade by bromoergocriptine in acromegalic patients.
Ishibashi M; Yamaji T; Kosaka K
J Clin Endocrinol Metab; 1978 Aug; 47(2):418-21. PubMed ID: 400720
[TBL] [Abstract][Full Text] [Related]
20. [Normalization of the GH response to L-DOPA in acromegalics after treatment with bromocriptine].
Carmina E; Lanzara P; Lo Coco R; Longo RA; Jannì A
Arch Sci Med (Torino); 1979; 136(3):421-5. PubMed ID: 549547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
